HematologyNews.net

Hematology Xagena

Final data from a phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic events ( VTE ) in patients treated with ISIS-FXI Rx undergoing total knee replacement surgery, o ...


The results from the STRATUS trial ( MM-010 ), a single-arm phase IIIb study of Pomalidomide ( Imnovid, Pomalyst ) plus low-dose Dexamethasone in patients with relapsed and refractory multiple myeloma ...


Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, has achieved an overall response rate of 66%, as assessed by International Harmonization Project response criteria ( n=19/29: 95% CI, 46-82 ), in tran ...


Positive results from a cohort of patients in its ongoing phase 1b trial ( CheckMate-039 ) which evaluated PD-1 immune checkpoint inhibitor, Nivolumab ( Opdivo), in patients with relapsed or refractor ...


Chronic ophthalmological complications of SCD include proliferative sickle retinopathy ( PSR ) and vitreous hemorrhage. They occur in up to 50% of individuals with SCD, and are found more frequently ...


The FDA ( Food and Drug Administration ) has approved a Supplemental New Drug Application ( sNDA ) for Eliquis ( Apixaban ) for the treatment of deep vein thrombosis ( DVT ) and pulmonary embolism ( P ...


Chronic kidney disease ( CKD ) is defined as either having a glomerular filtration rate ( GFR ) of less than 60 mL/min/1.73 mL for more than 3 months with or without kidney damage or having evidence o ...


Data from FIRST, an open-label phase III randomized study of continuous Lenalidomide ( Revlimid ) in combination with Dexamethasone in patients newly diagnosed with multiple myeloma ( NDMM ) who are n ...


Pulmonary hypertension ( PH ) is defined as an elevation of the resting mean pulmonary arterial pressure ( greater than or equal to 25 mmHg ) as determined by right heart catheterization ( RHC ). Th ...


Leg ulcers are a common complication of sickle cell disease ( SCD ) in general and sickle-cell anaemia ( SCA ) in particular. Leg ulceration was reported in all of the first four people with sickle ce ...


Patients with chronic lymphoid leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ) who experience short response duration or adverse cytogenetics have poor outcomes. Researchers have evaluated th ...


Avascular necrosis ( AVN, also known as aseptic necrosis, osteonecrosis, or ischemic necrosis ) is bone death due to compromised blood supply. Necrosis can occur when capillaries are occluded by sic ...


The Food and Drug Administration ( FDA ) has approved a supplemental New Drug Application ( sNDA ) for the once-daily use of Eltrombopag in patients with severe aplastic anaemia who have had an insuff ...


In sickle cell disease ( SCD ), pain is considered chronic if it lasts more than 3 months. People with sickle cell disease experience both nociceptive and neuropathic pain. Nociceptive pain is a hallm ...


The Pharmacovigilance Risk Assessment Committee ( PRAC ) of the European Medicines Agency ( EMA ) has concluded its review of Iclusig ( Ponatinib ) under the Article 20 referral procedure and has reco ...


Results from a phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia ( AML ) aged 65 or older and ineligible f ...


Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma ( DLBCL ) given a regimen of Rituximab ( MabThera, Rituxan ), Cyclophosphamide ( Endoxan ), Doxorubicin ( Adriamycin ), Vincr ...


Intravenous Rituximab ( MabThera, Rituxan ) is a mainstay of treatment for follicular lymphoma. A subcutaneous formulation that achieves equivalent Rituximab serum concentrations might improve conveni ...


Acute graft-versus-host disease ( GVHD ) remains a barrier to more widespread application of allogeneic haemopoietic stem-cell transplantation. Vorinostat ( Zolinza ) is an inhibitor of histone deac ...


Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour microenvironment. These checkpoints migh ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati